October 4, 2021
September 22, 2021
May 17, 2021
On May 17th, 2021, HRSA sent six pharmaceutical manufacturers letters stating that their restriction of 340B pricing to Contract Pharmacies is in direct violation of 340B statute.
February 1, 2022
January 3rd, 2022
January 1st, 2021
Effective December 1, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions from August 1, 2021, remain effective. Link to both notices below.
At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.
December 10th, 2021
Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.
Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.